• 1

Diabetic Foot Ulcers – Allogeneic

We are recruiting patients with diabetic foot ulcers (DFU) for a multicentric phase I/IIa clinical trial.

The aim of the trial is to examine the efficacy and safety of allogeneic ABCB5-positive mesenchymal stem cells (ABCB5+ MSCs) in patients with DFU. Primary endpoints are the percentage of wound size reduction and the occurrence of adverse events.

For this trial 37 patients will be recruited at seven sites in Germany.

For the manufacturing process of the allogeneic ABCB5+ MSCs we are using a patent hold by the Brigham and Women’s Hospital, Boston/USA, and the Children’s Hospital, Boston/USA, in cooperation with our scientific partner Prof. Dr. Markus Frank.

More information about the trial can be found HERE (ClinicalTrials.gov) or HERE (EU Clinical Trials Register).

Background information about the use of ABCB5+ MSCs in DFU can be found HERE.

Study Centers

If you are interested, please contact the corresponding center.

<< back

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.